Pressure BioSciences to Participate in FORCE Family Office June 30th Webinar: Revolutionizing the Development of Plant-Based Food Products
Investors, Analysts, and Advisors Invited to Attend this Real-Time, Interactive Presentation/Q&A Event
SOUTH EASTON, MA / ACCESSWIRE / June 30, 2022 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" and the "Company"), a leader in the development and sale of innovative, broadly enabling, pressure-based instruments, consumables, and specialty testing services to the worldwide food and beverage, biotherapeutics, and personal wellness industries, among others, today announced the Company's participation in the June 30th Revolutionizing the Development of Plant-Based Food Products webinar, sponsored by FORCE Family Office. This real-time, interactive "Presentation/Q&A Event" will cover the three pressure-based technology platforms of Pressure BioSciences, Inc., (PCT, BaroFold, UST™) with strong focus and emphasis on PBIO's Ultra Shear Technology™ (UST) platform. UST is a revolutionary technology platform that can process oil and water into highly stable and water-soluble nanoemulsions, which in turn are expected to significantly increase the bioavailability of the active ingredient contained in the oil.
The quest for finding alternative beverages that are healthier and environmentally sustainable but also appealing to the palate - such as plant protein-based drinks - is a rapidly growing market estimated to reach $41B by 2027 (MDC Market Report). A recent study published by The Ohio State University illuminated the unique capabilities of PBIO's UST platform for optimal formulation and processing of new and existing plant-based beverages. This presents enormous potential for PBIO…but how is the Company planning to take advantage of this remarkable opportunity. Attend and find out.
DATE: Thursday, June 30, 2022 (Noon ET)
PRESENTATION: Video Webcast
REGISTER: Click Here to Register for the June 30 FORCE Webinar
- Pressure BioSciences, Inc. (OTCQB: PBIO) announced on Wednesday, June 29th the initial distribution contract and roll-out time-table for the release of the Company's revolutionary Ultra Shear Technology™ (UST™) platform for the preparation of water soluble, long-term stable, highly bioavailable nanoemulsions of oil and water (e.g., CBD oil and water). Mr. Richard T. Schumacher, Founder and CEO, will be a panel participant. Joining Ric will be Dr. Alexander Lazarev, PBIO's Chief Science Officer.
- FORCE Family Office is the largest network of family offices in the United States. CEO Steven Saltzstein will be the Moderator of the webinar.
Selected Recent Key Announcements - PBIO
- PBIO Announces Commercial Release of the UST Platform with Contracted Launch for Estimated $3M of UST-Processed, Nanoemulsified CBD Spray for Oral Use
- Ohio State Data Illuminate Unique Capabilities of UST Platform for Optimal Formulation and Processing of New and Existing Plant Protein-Based Beverages
- PBIO Announces Early Access Program for UST Nanoemulsion Processing
About FORCE Family Office
FORCE is the largest network of family offices in the United States with a substantial and growing presence internationally. In 2020 alone, they hosted more than 160 events, a number they expect to exceed each year going forward. Their team is dedicated to helping family offices efficiently and successfully connect with private and public companies for co-investment, research, education, and philanthropy.
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions safely and reproducibly (e.g., cell lysis, biomolecule extraction). Our primary focus is the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the "BaroFold" technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology ("UST") platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.
Forward Looking Statements
This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied, or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," estimates," "predicts," "projects," "potential" or "continue" or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2021, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.
For more information about PBI and this press release, please click on the following website link:
Please visit us on Facebook, LinkedIn, and Twitter.
SOURCE: Pressure BioSciences Inc.
View source version on accesswire.com:
Released June 30, 2022